[Does plasmatic dilution influence the validity of PSA-tests?].

Prostate-specific antigen (PSA) testing remains a key diagnostic tool for prostate cancer. However, variability in PSA levels due to factors like blood volume can reduce test accuracy. Prior research has shown that PSA concentration alone may not reliably distinguish benign from malignant conditions. This gap motivated the exploration of volume-adjusted PSA metrics. No prior work had resolved how individual plasmatic volume affects diagnostic outcomes. Existing methods lack adjustments for physiological dilution effects. This paper's contribution is the introduction of modified PSA parameters. These new metrics aim to improve diagnostic precision by accounting for individual differences in blood volume. The study builds on established knowledge of PSA behavior in body fluids.

This study aimed to assess whether adjusting PSA measurements for individual plasmatic volume improves diagnostic accuracy. Researchers focused on patients who underwent prostate surgery, including adenomectomy and radical prostatectomy. They sought to compare traditional PSA metrics with newly developed volume-adjusted parameters. The motivation was to address limitations in current diagnostic approaches. The specific problem was the potential inaccuracy caused by physiological dilution. The study's goal was to determine if volume-based adjustments enhance cancer detection. By analyzing PSA in relation to blood volume, the team aimed to refine diagnostic thresholds. The study sought to provide evidence for improved preoperative evaluation methods.

The research involved a retrospective analysis of patients who had undergone prostate surgery. Data were collected from 32 adenomectomy and 60 prostatectomy cases. Researchers calculated PSA density (PSAD) and two new metrics: mPSA (Vp) and mPSAD (Vp). These metrics adjusted PSA values based on individual plasmatic volume. The modified Retzlaff formula was used to derive these parameters. Receiver operating characteristic (ROC) curves were generated to compare diagnostic performance. Statistical analyses included area under the curve (AUC), sensitivity, and specificity. The study evaluated diagnostic accuracy across different PSA ranges and patient groups.

The study found that PSAD and mPSAD (Vp) significantly improved diagnostic accuracy compared to traditional t-PSA and mPSA (Vp). Within the full PSA range (0.1–88.4 microg/L), PSAD and mPSAD (Vp) achieved AUCs of 0.803 and 0.806, respectively. Traditional t-PSA and mPSA (Vp) had lower AUCs of 0.531. In the 4.0–10.0 microg/L range, PSAD reached an AUC of 0.931. mPSAD (Vp) achieved the highest AUC of 0.947 in this range. These results suggest volume-adjusted metrics enhance cancer detection. However, the improvement in mPSAD (Vp) did not reach statistical significance. The findings support the hypothesis that volume normalization improves PSA test validity.

The authors propose that adjusting PSA measurements for individual plasmatic volume improves diagnostic accuracy. Their findings suggest that volume-adjusted metrics like PSAD and mPSAD (Vp) outperform traditional t-PSA in distinguishing benign from malignant conditions. The study highlights the potential of volume-based adjustments to refine cancer detection. These results may guide the development of more accurate preoperative diagnostic tools. The authors suggest that further research is needed to validate these metrics in larger populations. They emphasize the need for devices that measure prostate tissue volumes accurately. The study supports the idea that physiological factors should be integrated into PSA testing. The authors conclude that volume normalization could optimize the detection of curable prostate cancer cases.